Navigation Links
Biodel Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins: Initiate Phase 2 in 2011; Phase 3 Pivotal Trials in 2012
Date:3/14/2011

DANBURY, Conn., Mar. 14, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) announced today that it has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates.  The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed meal time insulin analogs while maintaining an injection site tolerability profile comparable to currently marketed insulins.  Biodel plans to test these formulations in a Phase 1 clinical trial of approximately 18 patients with Type 1 diabetes.  This study is designed as a double blinded, three-period cross over trial in which patients will receive one subcutaneous injection of BIOD-105, BIOD-107 and Humalog® each on separate occasions.  This study, expected to be completed in the third calendar quarter of 2011, will evaluate pharmacokinetic, pharmacodynamic and tolerability profiles of the two experimental insulins relative to that of Humalog®.  In parallel with this subcutaneous injection study, Biodel plans to utilize a similar design to conduct a clinical pump study this year.

If this Phase 1 study is successful, Biodel now anticipates initiating a Phase 2 study in patients with Type 1 diabetes in the fourth calendar quarter of 2011.  The Phase 2 study is intended to follow the same overall design that would be implemented in Phase 3 studies, which would include two separate pivotal trials-- one in patients with Type 1 diabetes, and the other in patients with Type 2 diabetes.  Biodel recently received initial guidance from the U.S. Food and Drug Administration (FDA) on the design of two pivotal Phase 3 clinical trials.  Based on this guidance, Biodel plans to design the Phase 2 and 3 studies as randomized parallel group studies u
'/>"/>

SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
2. Biodel Inc. to Present at the Roth 23rd Annual OC Growth Stock Conference on March 16, 2011
3. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
4. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
5. Biodel Reports First Quarter Fiscal Year 2011 Financial Results
6. Biodel to Report First Quarter Fiscal Year 2011 Financial Results on February 3, 2011
7. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
8. Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer
9. Biodel Reports Fourth Quarter and Fiscal Year 2010 Financial Results
10. Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting
11. Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Patient engagement has become a ... are turning to an assortment of marketing activities ... of this evolving approach to patient engagement, marketers ... engage patients throughout their experiences with a disease ... mapping the patient journey and employing a consumer ...
(Date:7/11/2014)... According to a new ... Material, Application (Healthcare, Homeland security, Industrial application, Nuclear ... Hand-Held Instruments, Fixed, and Installed Instruments) & Geography ... by MarketsandMarkets, the Scintillator Market is expected to ... to 2020, and reach $479.16 Million in 2020. ...
(Date:7/11/2014)... July 11, 2014 On ... down 0.52%, the Dow Jones Industrial Average finished the day ... 1,964.68, down 0.41%. The losses were broad based as eight ... S&P 500 Health Care Sector Index ended the day at ... the last one month. Investor-Edge has initiated coverage on the ...
Breaking Medicine Technology:New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4
(Date:7/11/2014)... The report, “Specialty Synthetic Fibers & Glass Fiber ... defines and segments the specialty synthetic fibers and ... of the volumes and values of types such ... UHMW Polyethylene, carbon fiber, partially oxidized polyacrylonitrile fiber, ... fiber, and liquid crystal polymer fiber and glass ...
(Date:7/11/2014)... July 11, 2014 Datalogic brings a ... improving sanitation hospital wide. With their new Gryphon ... of disease, like the devastating MRSA, which claimed 5,500 ... GD4400-HC 2D and the Gryphon GM4400-HC 2D ... and can even read barcodes off of troublesome LCD ...
(Date:7/11/2014)... July 11, 2014 Operators ... $50 billion in fuel costs now that ... current GHG standards are phasing ... it upon themselves to install new features ... 1.    Idle reduction technologies , 2.    Efficient driveline components ...
(Date:7/11/2014)... 2014 (HealthDay News) -- Children who have emergency ... complications and potentially even death than those who ... However, the Johns Hopkins researchers noted that ... researchers analyzed data on nearly 440,000 simple emergency ... over a 22-year period. The surgeries are ...
(Date:7/11/2014)... Ticket Down is a reliable source ... When it comes to the summer concert schedule, it just ... native is one of the biggest names in country music and ... currently out on his “That’s My Kind of Night” tour featuring ... will be making through the rest of the summer and into ...
Breaking Medicine News(10 mins):Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3
... 31 ev3 Inc. (Nasdaq:,EVVV) today announced that Pat ... are scheduled to present at the,Canaccord Adams 28th Annual ... p.m. Eastern Time. The Canaccord Adams 28th Annual Global,Growth ... Boston,Massachusetts., To access the webcast, go to the ...
... Call Today at 5:00 p.m. Eastern Time -, ... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... progress and financial results,for the second quarter ended ... are to develop picoplatin as an oncology,platform compound ...
... July 31 Mylan Inc. (NYSE: MYL ),today ... stock,issuance, the company has declared its quarterly dividend of ... 6.5% and a liquidation,preference of $1,000.00 per share) payable ... record as of August 1, 2008., Mylan Inc., ...
... PARAMUS, N.J., July 31 Smart Balance Inc.,(Nasdaq: ... marketing organization,today. Richard McWilliams has been named to ... brands, reporting to Gregory Venner, executive,vice president and ... the marketing efforts for the Company,s core brands., ...
... ARBOR, Mich. Pat Phalin learned she had hearing loss ... her local school. The pupils heard sounds she could not ... a pattern in his wife,s family history. Her mother, grandfather ... the Phalins, children had hearing problems before he reached school ...
... ST. LOUIS, July 31 Stereotaxis, Inc. (Nasdaq:,STXS) ... results for the,second quarter ended June 30, 2008, ... The Company will host a conference call and ... Eastern Time to discuss the Company,s,second quarter results ...
Cached Medicine News:Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 2Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 3Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 4Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 5Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 6Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 7Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 8Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 9Health News:Smart Balance Announces Marketing Organization Appointment 2Health News:Inherited form of hearing loss stems from gene mutation 2Health News:Inherited form of hearing loss stems from gene mutation 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: